Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487706 | 0.90 | PPARG (0.41) | HTR2ASLC6A4KCNH2PPARGPPARD | |
| SCHEMBL3488807 | 0.90 | SLC1A3 (0.45) | PPARGPPARDPPARACARM1PRMT6 | |
| SCHEMBL3488403 | 0.88 | SMN1; SMN2 (0.42) | HTR2ASLC6A4KCNH2PPARGPPARD | |
| SCHEMBL3487417 | 0.86 | HTR2A (0.46) | HTR2ASLC6A4KCNH2CHEK2AKR1B1 | |
| SCHEMBL3488332 | 0.85 | GCK (0.46) | PPARGPPARDPPARACARM1PRMT6 | |
| SCHEMBL3488269 | 0.84 | EGLN1 (0.42) | PPARGPPARDPPARAGCK | |
| SCHEMBL3487252 | 0.84 | GCK (0.41) | HTR2ASLC6A4KCNH2PPARGPPARD | |
| SCHEMBL3488176 | 0.84 | TEAD4 (0.46) | GCKMMP13 | |
| SCHEMBL3488032 | 0.84 | SLC6A4 (0.45) | HTR2ASLC6A4KCNH2PPARGPPARA | |
| SCHEMBL3487994 | 0.83 | ALDH1A1 (0.42) | CHRM4GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2138484-B1 | FUSED BICYCLIC HETEROARYL DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-20100048564-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2138484-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048564-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | PPARG, GPR119, PPARA | HTR2A 1485/4885SLC6A4 1449/4885KCNH2 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.